Suppr超能文献

双重双重作用?文拉法辛与米氮平联合治疗抑郁症。

Dual-dual action? Combining venlafaxine and mirtazapine in the treatment of depression.

作者信息

Malhi Gin S, Ng Felicity, Berk Michael

机构信息

Discipline of Psychological Medicine, University of Sydney, Sydney, New South Wales, Australia.

出版信息

Aust N Z J Psychiatry. 2008 Apr;42(4):346-9. doi: 10.1080/00048670701881587.

Abstract

OBJECTIVE

Venlafaxine and mirtazapine in combination are increasingly used in clinical practice to treat treatment-refractory depression. Putative efficacy for this combination of antidepressants, beyond that of monotherapy, stems from their synergistic actions. This paper describes a prospective case series that examined the efficacy of the venlafaxine-mirtazapine combination in the treatment of depressed patients who had failed at least one antidepressant trial.

METHOD

Twenty-two depressed patients with major depression were treated with venlafaxine and mirtazapine in combination for an average of just under 8 weeks. Baseline ratings on the 17-item Hamilton Depression Rating Scale (HAM-D(17)), Montgomery-Asberg Depression Rating Scale (MADRS) and the Clinical Global Impression-Severity Scale (CGI-S) were repeated at end-point, determined by the naturalistic termination of the depressive treatment episode or the discontinuation of the combination treatment due to adverse effects. The length of treatment until end-point was documented for each patient. Descriptive statistics were used on the collated data.

RESULTS

At baseline, mean scores were 28.8 (SD=3.8) for HAM-D(17), 30.1 (SD=5.8) for MADRS, and 4.5 (SD=0.5) for CGI-S, reflecting a cohort at the moderate to severe end of the spectrum. At end-point, mean absolute scores were 10.2 (SD=4.7) for HAM-D(17), 10.8 (SD=4.6) for MADRS, and 2.3 (SD=0.6) for CGI-S. Mean change from baseline was 18.6 (SD=6.4) for HAM-D(17), 19.3 (SD=6.8) for MADRS, and 2.3 (SD=0.6) for CGI-S. Mean duration of treatment was approximately 8 weeks, producing a response rate of 81.8% and a remission rate of 27.3%. Only one patient was unable to tolerate the combination although nearly half (10) had significant side-effects during treatment.

CONCLUSION

This study demonstrates relatively high response and remission rates that are encouraging and contribute to the efficacy database for this antidepressant combination. Further studies using randomized controlled designs are needed.

摘要

目的

文拉法辛与米氮平联合用药在临床实践中越来越多地用于治疗难治性抑郁症。这种抗抑郁药联合使用的假定疗效高于单一疗法,源于它们的协同作用。本文描述了一项前瞻性病例系列研究,该研究考察了文拉法辛 - 米氮平联合用药对至少一次抗抑郁药试验失败的抑郁症患者的疗效。

方法

22名重度抑郁症患者接受文拉法辛与米氮平联合治疗,平均治疗时间略少于8周。在终点时重复进行17项汉密尔顿抑郁量表(HAM - D(17))、蒙哥马利 - 阿斯伯格抑郁量表(MADRS)和临床总体印象 - 严重程度量表(CGI - S)的基线评分,终点由抑郁治疗阶段的自然终止或因不良反应而停用联合治疗确定。记录每位患者直至终点的治疗时长。对整理后的数据进行描述性统计。

结果

在基线时,HAM - D(17)的平均评分为28.8(标准差 = 3.8),MADRS为30.1(标准差 = 5.8),CGI - S为4.5(标准差 = 0.5),表明该队列处于中重度范围。在终点时,HAM - D(17)的平均绝对评分为10.2(标准差 = 4.7),MADRS为10.8(标准差 = 4.6),CGI - S为2.3(标准差 = 0.6)。与基线相比的平均变化为:HAM - D(17)为18.6(标准差 = 6.4),MADRS为19.3(标准差 = 6.8),CGI - S为2.3(标准差 = 0.6)。平均治疗时长约为8周,有效率为81.8%,缓解率为27.3%。尽管近一半(10名)患者在治疗期间有明显副作用,但只有一名患者无法耐受联合用药。

结论

本研究显示出相对较高的有效率和缓解率,令人鼓舞,并为这种抗抑郁药联合用药的疗效数据库增添了内容。需要进一步采用随机对照设计进行研究。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验